OBIO vs. QIPT, CLPT, DRTS, PROF, DCTH, TELA, ARAY, STIM, KRMD, and RCEL
Should you be buying Orchestra BioMed stock or one of its competitors? The main competitors of Orchestra BioMed include Quipt Home Medical (QIPT), ClearPoint Neuro (CLPT), Alpha Tau Medical (DRTS), Profound Medical (PROF), Delcath Systems (DCTH), TELA Bio (TELA), Accuray (ARAY), Neuronetics (STIM), KORU Medical Systems (KRMD), and AVITA Medical (RCEL). These companies are all part of the "surgical & medical instruments" industry.
Orchestra BioMed (NASDAQ:OBIO) and Quipt Home Medical (NASDAQ:QIPT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability, institutional ownership, dividends and risk.
Quipt Home Medical received 18 more outperform votes than Orchestra BioMed when rated by MarketBeat users. However, 100.00% of users gave Orchestra BioMed an outperform vote while only 82.76% of users gave Quipt Home Medical an outperform vote.
Quipt Home Medical has a net margin of -1.50% compared to Orchestra BioMed's net margin of -1,779.71%. Quipt Home Medical's return on equity of -3.57% beat Orchestra BioMed's return on equity.
Orchestra BioMed has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500. Comparatively, Quipt Home Medical has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.
Orchestra BioMed currently has a consensus target price of $17.00, indicating a potential upside of 260.93%. Quipt Home Medical has a consensus target price of $10.00, indicating a potential upside of 148.14%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, equities research analysts plainly believe Orchestra BioMed is more favorable than Quipt Home Medical.
In the previous week, Quipt Home Medical had 3 more articles in the media than Orchestra BioMed. MarketBeat recorded 4 mentions for Quipt Home Medical and 1 mentions for Orchestra BioMed. Orchestra BioMed's average media sentiment score of 1.87 beat Quipt Home Medical's score of 0.47 indicating that Orchestra BioMed is being referred to more favorably in the media.
53.5% of Orchestra BioMed shares are owned by institutional investors. Comparatively, 42.9% of Quipt Home Medical shares are owned by institutional investors. 6.7% of Orchestra BioMed shares are owned by company insiders. Comparatively, 4.2% of Quipt Home Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Quipt Home Medical has higher revenue and earnings than Orchestra BioMed. Quipt Home Medical is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.
Summary
Orchestra BioMed and Quipt Home Medical tied by winning 9 of the 18 factors compared between the two stocks.
Get Orchestra BioMed News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Orchestra BioMed Competitors List
Related Companies and Tools
